Aurinia Pharmaceuticals (NASDAQ:AUPH) Price Target Raised to $30.00

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its target price boosted by equities researchers at Cantor Fitzgerald from $24.00 to $30.00 in a report issued on Thursday, The Fly reports. Cantor Fitzgerald’s target price would suggest a potential upside of 94.30% from the company’s current price.

Several other research firms have also weighed in on AUPH. Bloom Burton reissued a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 2nd. HC Wainwright set a $25.00 target price on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 1st. BidaskClub upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 30th. Royal Bank of Canada upped their price target on Aurinia Pharmaceuticals from $11.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Oppenheimer increased their price target on shares of Aurinia Pharmaceuticals from $14.00 to $22.00 in a research report on Thursday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $18.46.

AUPH stock opened at $15.44 on Thursday. The business’s fifty day moving average is $6.08 and its 200-day moving average is $6.03. The company has a market cap of $1.46 billion, a P/E ratio of -20.32 and a beta of 1.25. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $17.48.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%. The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.05 million. Analysts predict that Aurinia Pharmaceuticals will post -0.71 EPS for the current year.

Hedge funds have recently made changes to their positions in the company. Vivo Capital LLC increased its position in shares of Aurinia Pharmaceuticals by 57.7% in the 2nd quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock valued at $12,592,000 after buying an additional 700,333 shares in the last quarter. Orbimed Advisors LLC raised its stake in Aurinia Pharmaceuticals by 12.1% during the 2nd quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock worth $23,234,000 after buying an additional 381,192 shares during the period. SG Americas Securities LLC bought a new position in Aurinia Pharmaceuticals during the third quarter worth about $246,000. BlackRock Inc. lifted its holdings in Aurinia Pharmaceuticals by 3.1% during the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after acquiring an additional 28,129 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Aurinia Pharmaceuticals during the third quarter worth about $122,000. 27.00% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Read More: What is Forex?

The Fly

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit